Array Biopharma (NASDAQ: ARRY) is really hitting on all cylinders with eight-wholly owned development programs and a rich portfolio of discovery programs. Let’s take a closer look under the hood…shall we?ARRY 162 – neared completion of a Phase I trial with of adding to methotrexate in patients with stable rheumatoid arthritis. Plans are to begin [...]